Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for per share in cash, leading to a total enterprise value of an estimated .4 billion.1
“We are incredibly proud that Pfizer has recognized the value Array has brought to patients and our remarkable legacy discovering and advancing molecules with great potential to impact and extend the lives of patients in critical need,” Ron Squarer, Array chief executive officer, said in a press release. “Pfizer shares our commitment to patients and a passion for advancing science to develop even more options for individuals with unmet needs. We’re excited our team will have access to world-class resources and a broader research platform to continue this critical work.”
- Pfizer to Acquire Array BioPharma. Pfizer. Published June 17, 2019. https://bit.ly/2WN3dJG. Accessed June 17, 2019.
- Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints Of ORR And OS In Phase 3 Beacon Crc Trial Interim Analysis For The Treatment Of Braf(V600e)-Mutant Metastatic Colorectal Cancer. Array BioPharma. Published May 21, 2019. https://bit.ly/2YFrjCw. Accessed May 21, 2019.
... to read the full story